Crocetin / LDH Cancer Research Results

Cro, Crocetin: Click to Expand ⟱
Features:
Crocetin is a carotenoid pigment found in saffron (Crocus sativus) and has been studied for its potential anti-cancer properties. Research has shown that crocetin may have anti-tumor and anti-proliferative effects, inhibiting the growth of various types of cancer cells.
Crocetin is a carotenoid dicarboxylic acid derived from saffron (Crocus sativus) and is a metabolite of crocin. It is lipophilic and more bioavailable than crocin. In cancer research, crocetin is studied mainly in preclinical models, where it appears to influence apoptosis, inflammation, angiogenesis, and redox signaling. It is not a primary cytotoxic chemotherapeutic, but a signaling and stress-modulating compound.
Mechanistic themes reported:
-NF-κB suppression
-PI3K/AKT pathway modulation
-MAPK signaling effects
-Apoptosis induction (mitochondrial pathway)
-Anti-angiogenic signaling (VEGF reduction)
-Redox modulation (context-dependent antioxidant / pro-oxidant behavior)

Evidence level: predominantly cell culture and animal models.
Reported to modulate glycolytic metabolism and lactate production (model-dependent); LDH5 inhibition has been reported preclinically, but clinical relevance and achievable tumor exposure are not established.


Crocetin — Crocetin is a saffron/gardenia-derived apocarotenoid dicarboxylic acid and the aglycone bioactive metabolite of crocin. It is formally a natural-product carotenoid derivative rather than an approved anticancer drug. Standard abbreviations include Cro and, less commonly, trans-crocetin or crocetic acid. It originates primarily from Crocus sativus stigma and Gardenia jasminoides fruit, with crocin serving as a glycosylated precursor that is hydrolyzed to crocetin after oral intake. In oncology, crocetin is best classified as a preclinical signaling, redox, metabolism, and apoptosis-modulating compound with limited direct human cancer-treatment evidence.

Primary mechanisms (ranked):

  1. Mitochondrial apoptosis induction through Bax/Bcl-2 shift, caspase activation, mitochondrial membrane potential disruption, and cell-cycle checkpoint effects.
  2. Suppression of inflammatory and survival signaling, especially NF-κB-linked cytokine, COX-2, VEGF, and invasion programs.
  3. PI3K/AKT, MAPK, STAT3, SHH, and related growth-pathway modulation, with direction varying by cancer model.
  4. Antiglycolytic activity through LDH5/LDHA-linked lactate metabolism effects; stronger as a preclinical metabolic hypothesis than as a clinically validated anticancer axis.
  5. Anti-angiogenic and anti-invasive modulation, including VEGF, MMPs, EMT markers, and migration suppression in selected models.
  6. Redox modulation, generally antioxidant/cytoprotective in normal-tissue injury models but context-dependent in cancer cells; NRF2/HO-1 activation is better supported in normal-cell injury models than as a core anticancer mechanism.
  7. Adjunct chemosensitization, reported with vincristine and cisplatin in cell models, but not clinically established.

Bioavailability / PK relevance: Oral crocin is poorly absorbed intact and is largely converted to crocetin by intestinal and microbial glycosidase activity. Crocetin itself appears in plasma after oral crocin or crocetin exposure, often as free crocetin and glucuronide conjugates, but poor solubility, formulation dependence, intestinal metabolism, and uncertain tumor-tissue exposure constrain translation.

In-vitro vs systemic exposure relevance: Many anticancer cell studies use crocetin in the approximate 50–800 µM range, with several key studies around 60–240 µM or higher. These concentrations likely exceed typical exposure from dietary saffron or ordinary oral supplement use, so in-vitro cytotoxic and chemosensitizing effects should be treated as high-concentration/preclinical unless supported by formulation-specific PK data.

Clinical evidence status: Preclinical for oncology. There are cell-culture and animal tumor data, including pancreatic, colorectal, gastric, cervical/ovarian, prostate, and hepatocellular models, plus limited adjunct combination data. Human clinical evidence for isolated crocetin is mainly non-oncology or safety-oriented, while oncology-related human trials are more often crocin/saffron adjunctive or supportive-care contexts rather than crocetin as an anticancer therapy.

Crocetin Cancer Mechanism Table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mitochondrial apoptosis and cell-cycle checkpoints Bax ↑; Bcl-2 ↓; caspase-3/9 ↑; p21 ↑; G1/S/G2-M arrest ↑ (model-dependent) Apoptosis ↓ in injury models; mitochondrial protection ↑ (context-dependent) G Apoptosis induction and cytostasis Core anticancer mechanism across multiple models; normal-cell effects often move in the opposite protective direction under oxidative or inflammatory injury.
2 NF-κB inflammatory survival signaling NF-κB ↓; IL-6 ↓; IL-8 ↓; COX-2 ↓; iNOS ↓; inflammatory transcription ↓ NF-κB-driven inflammation ↓ R, G Anti-inflammatory tumor suppression Central to anti-invasive and anti-angiogenic interpretations; strongest where inflammation-linked tumor progression is active.
3 PI3K / AKT and survival kinase signaling p-AKT ↓ or pathway suppression ↑ (model-dependent); survival signaling ↓ p-AKT ↑ in some endothelial/cardioprotective injury models R, G Growth and survival pathway modulation Direction is highly context-dependent; cancer-cell suppression should not be generalized to all normal tissues.
4 MAPK stress signaling p38 MAPK ↑; ERK/JNK effects variable; migration ↓ in HCT-116 models ↔ or stress signaling normalization (context-dependent) P, R, G Stress-pathway reprogramming Important in colorectal models, but direction and therapeutic implication vary by tumor genotype and drug context.
5 LDH5 / lactate metabolism LDH5 activity ↓; LDHA protein ↓; lactate production ↓; glycolytic phenotype ↓ (model-dependent) ↔ R, G Antiglycolytic pressure Mechanistically attractive because LDH5 is a Warburg-metabolism target, but evidence is still mainly biochemical and preclinical.
6 Angiogenesis and VEGF axis VEGF ↓; EGFR phosphorylation ↓; angiogenic signaling ↓ ↔ or vascular protection ↑ in injury models G Anti-angiogenic support Usually secondary to NF-κB, AKT, EGFR, and inflammatory pathway changes rather than a uniquely direct anti-VEGF drug-like mechanism.
7 Migration / invasion and EMT MMP-2 ↓; MMP-9 ↓; uPA ↓; N-cadherin ↓; β-catenin ↓; E-cadherin ↑ ↔ G Anti-invasive phenotype Relevant to metastasis biology but mostly based on in-vitro migration/invasion and selected xenograft models.
8 ROS and oxidative stress balance ROS effects mixed; oxidative stress ↓ in some melanoma/cancer models; apoptosis may occur without a simple ROS ↑ pattern ROS ↓; MDA ↓; lipid peroxidation ↓; SOD/GPx/GSH defenses ↑ P, R, G Redox buffering and stress modulation More clearly cytoprotective in normal-cell injury models than selectively pro-oxidant in cancer. Not a universal cancer ROS increaser.
9 NRF2 / HO-1 antioxidant response ↔ or uncertain; cancer-specific NRF2 direction is not well established NRF2 ↑; HO-1 ↑ in oxidative/inflammatory injury models R, G Normal-tissue cytoprotection Relevant as a protective/stress-response axis. Because sustained NRF2 activation can support therapy resistance in some cancers, this is a context-sensitive translation issue.
10 STAT3 / JAK / Src signaling STAT3 activation ↓; nuclear accumulation ↓; upstream Src/JAK signaling ↓ (reported in hepatocellular models) ↔ R, G Proliferation and inflammatory transcription suppression Secondary but potentially meaningful where STAT3-driven inflammation/survival signaling is dominant.
11 SHH / Gli cancer stem and gastric signaling SHH ↓; Gli1 ↓; DCLK1 ↓; cancer stem phenotype ↓ (model-dependent) ↔ G Stemness and developmental pathway modulation Potentially relevant in pancreatic and gastric contexts, but not yet a broad validated crocetin mechanism.
12 Chemosensitization Vincristine sensitivity ↑; cisplatin-induced apoptosis ↑ in selected models Normal-tissue protection possible but not established for oncology treatment protocols G Adjunct sensitization Combination evidence is preclinical. Antioxidant and NRF2-linked effects make timing, concentration, and chemotherapy mechanism important.
13 Clinical Translation Constraint Effective in-vitro concentrations often high; tumor exposure uncertain; human oncology efficacy not established Generally tolerated in limited human non-oncology studies, but cancer-treatment safety is not established G Evidence and delivery limitation Key constraints are poor solubility, formulation dependence, metabolism from crocin to crocetin, uncertain achievable tumor concentration, and lack of definitive anticancer trials.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (early redox and signaling interactions)
  • R: 30 min–3 hr (NF-κB / PI3K / MAPK modulation)
  • G: >3 hr (apoptosis, angiogenesis, and phenotype-level outcomes)


Crocetin and Alzheimer’s disease context — Crocetin is relevant to AD mainly as part of the saffron/crocin/crocetin evidence cluster rather than as a clinically established isolated AD drug. Mechanistic support includes antioxidant protection, anti-inflammatory signaling, Aβ-related effects, AChE inhibition signals from saffron constituents, ER-stress/apoptosis reduction, and possible BBB/gut-microbiome-mediated effects. Human RCT evidence is stronger for saffron extract than for purified crocetin.

Crocetin AD-Relevant Mechanism Table

Rank Pathway / Axis Modulation TSF Primary Effect Notes / Interpretation
1 Oxidative stress and lipid peroxidation ROS ↓; MDA ↓; SOD/GPx/GSH ↑ P, R, G Neuroprotection Most consistent non-cancer mechanism; often demonstrated in injury or neurodegeneration models using saffron, crocin, or crocetin-related exposure.
2 Neuroinflammation NF-κB ↓; TNF-α ↓; IL-1β ↓; inflammatory tone ↓ R, G Anti-inflammatory support Likely contributes to cognitive and neuroprotective outcomes, but source specificity may vary between saffron extract, crocin, and crocetin.
3 Aβ aggregation / amyloid burden Aβ aggregation ↓; amyloid toxicity ↓ (model-dependent) G Protein aggregation modulation Relevant for AD indexing, but human clinical claims should be tied to saffron/crocin trial evidence rather than isolated crocetin unless directly tested.
4 Cholinergic signaling AChE ↓; ChAT ↑ (reported) R, G Neurotransmission support AChE inhibition is plausible for saffron constituents; compound-specific potency and clinical relevance require careful source attribution.
5 ER stress and apoptosis CHOP ↓; GRP78/BiP ↓; caspase-3 ↓; Bax ↓; Bcl-2 ↑ G Stress and cell-death reduction Protective direction is opposite to the desired cancer-cell apoptosis direction, so disease context must be explicit.
6 PK / CNS exposure constraint Crocin → crocetin; plasma crocetin ↑; BBB exposure uncertain R, G Translation constraint Recent metabolism data support intestinal conversion to crocetin, but direct brain exposure and active metabolites remain incompletely resolved.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (early redox and signaling interactions)
  • R: 30 min–3 hr (NF-κB / PI3K / MAPK modulation)
  • G: >3 hr (apoptosis, angiogenesis, and phenotype-level outcomes)
LDH, Lactate Dehydrogenase: Click to Expand ⟱
Source:
Type:
LDH is a general term that refers to the enzyme that catalyzes the interconversion of lactate and pyruvate. LDH is a tetrameric enzyme, meaning it is composed of four subunits.
LDH refers to the enzyme as a whole, while LDHA specifically refers to the M subunit. Elevated LDHA levels are often associated with poor prognosis and aggressive tumor behavior, similar to elevated LDH levels.
leakage of LDH is a well-known indicator of cell membrane integrity and cell viability [35]. LDH leakage results from the breakdown of the plasma membrane and alterations in membrane permeability, and is widely used as a cytotoxicity endpoint.

However, it's worth noting that some studies have shown that LDHA is a more specific and sensitive biomarker for cancer than total LDH, as it is more closely associated with the Warburg effect and cancer metabolism.

Dysregulated LDH activity contributes significantly to cancer development, promoting the Warburg effect (Chen et al., 2007), which involves increased glucose uptake and lactate production, even in the presence of oxygen, to meet the energy demands of rapidly proliferating cancer cells (Warburg and Minami, 1923; Dai et al., 2016b). LDHA overexpression favors pyruvate to lactate conversion, leading to tumor microenvironment acidification and aiding cancer progression and metastasis.

Inhibitors:
Flavonoids, a group of polyphenols abundant in fruit, vegetables, and medicinal plants, function as LDH inhibitors.
LDH is used as a clinical biomarker for Synthetic liver function, nutrition

Tier A — Direct LDH Enzyme Inhibitors (Validated Catalytic Inhibition)

Rank Compound Type LDH Target Potency Level Primary Effect Notes
1 NCI-006 Research drug LDHA / LDHB High (in vivo active) Potent glycolysis suppression Modern benchmark LDH inhibitor used in metabolic oncology models.
2 (R)-GNE-140 Research drug LDHA (±LDHB) High (nM range reported) Lactate production ↓ Widely used experimental LDH inhibitor.
3 FX11 Research drug LDHA High (μM range) Metabolic crisis in LDHA-dependent tumors Classic LDHA inhibitor; often increases ROS secondary to metabolic stress.
4 Oxamate Tool compound LDH (pyruvate-competitive) Moderate (mM cellular use) Reduces lactate flux Classical LDH inhibitor; requires high concentrations in cells.
5 Gossypol Natural product derivative LDHA Moderate–High Glycolysis inhibition Also has other targets; safety considerations apply.
6 Galloflavin Natural compound LDH isoforms Moderate Lactate production ↓ One of the better-supported “natural-like” LDH inhibitors.

Tier B — Indirect LDH-Axis Modulators (Glycolysis / Lactate Reduction Without Confirmed Direct Catalytic Inhibition)

Rank Compound Mechanism Type LDH Claim Type Primary Axis Notes / Caution
1 Lonidamine MCT/MPC modulation Lactate axis inhibition Metabolic transport blockade Better classified as lactate/pyruvate transport modulator.
2 Stiripentol Repurposed drug LDH pathway modulation Metabolic axis modulation Emerging oncology interest; primarily neurological drug.
3 Quercetin Flavonoid Reported LDH inhibition (mixed evidence) NF-κB / PI3K modulation Often LDH-release confusion; direct enzymatic proof limited.
4 Ursolic acid Triterpenoid Reported LDH interaction Warburg modulation More credible as metabolic signaling modulator.
5 Fisetin Flavonoid Docking / indirect reports Apoptosis / survival signaling Enzyme inhibition not well validated.
6 Resveratrol Polyphenol Indirect glycolysis suppression AMPK / HIF-1α modulation Reduces lactate via upstream signaling.
7 Curcumin Polyphenol Indirect LDH expression modulation Inflammation + metabolic signaling Bioavailability limits translational strength.
8 Berberine Alkaloid Indirect metabolic modulation AMPK activation Closer to metformin-like metabolic pressure.
9 Honokiol Lignan Indirect glycolysis effects Survival pathway suppression Not validated as catalytic LDH inhibitor.
10 Silibinin Flavonolignan Mixed / indirect reports Inflammation + metabolic axis Often misclassified as LDH inhibitor.
11 Kaempferol Flavonoid Often LDH-release marker confusion Glucose transport / signaling Do not list as direct LDH inhibitor without enzyme data.
12 Oleanolic acid / Limonin / Allicin / Taurine Natural compounds Weak / indirect evidence General metabolic modulation Should not be categorized as true LDH inhibitors.

Tier A = Direct catalytic LDH inhibition (enzyme-level validation).
Tier B = Indirect lactate reduction or glycolytic modulation without strong catalytic inhibition evidence.
Important: LDH release assays (cell damage marker) are not proof of LDH enzymatic inhibition.



Scientific Papers found: Click to Expand⟱
945- Cro,    Characterization of the Saffron Derivative Crocetin as an Inhibitor of Human Lactate Dehydrogenase 5 in the Antiglycolytic Approach against Cancer
- in-vitro, Lung, A549 - in-vitro, Cerv, HeLa
LDH↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

LDH↓, 1,  

Clinical Biomarkers ⓘ

LDH↓, 1,  
Total Targets: 2

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: LDH, Lactate Dehydrogenase
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:249  Target#:906  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page